Regeneron signs $2.32 billion deal with Parabilis for Helicon conjugates
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance
By leveraging digital screening and remote consultation, the medical community is moving beyond the confines of the clinic
She brings extensive expertise in managing global and domestic procurement operations
The therapy is suited for patients with severe valve leakage who face elevated surgical risk due to advanced age, frailty, or multiple medical complications
The new facility at Byatarayanapura introduces Karnataka’s first Elekta Unity MR-Linac technology
Combined footprint expands to 420 hearing care centres across India
The product has received tentative USFDA approval, Health Canada notice of compliance, and Indian regulatory approval
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
The country’s strength lies not just in technology availability but in adoption behaviour
Subscribe To Our Newsletter & Stay Updated